BLRX

BioLine RX Ltd

Add to Watchlist

Advanced Chart

3.160

-0.120(-3.660%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.220

Open

3.1414

VWAP

3.17

Vol

8.93K

Mkt Cap

11.76M

Low

3.1414

Amount

28.27K

EV/EBITDA(TTM)

Total Shares

79.94M

7.85M

EV/OCF(TTM)

P/S(TTM)

0.23

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

2.05M

-58.53%

1.83M

-66.12%

1.48M

-78.4%

Estimates Revision

The market is revising Upward the revenue expectations for BioLineRx Ltd. (BLRX) for FY2025, with the revenue forecasts being adjusted by 35.71% over the past three months. During the same period, the stock price has changed by -5.39%.

Revenue Estimates for FY2025

Revise Upward

+35.71%

In Past 3 Month

Stock Price

Go Down

-5.39%

In Past 3 Month

2 Analyst Rating

722.78% Upside

Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

722.78% Upside

Current: 3.160

Low

26.00

Averages

26.00

High

26.00

722.78% Upside

Current: 3.160

Low

26.00

Averages

26.00

High

26.00

Jones Trading

Justin Walsh

Strong Buy

Hold

Downgrades

n/a

2025-04-02

Reason

Jones Trading

Justin Walsh

Price Target

n/a

2025-04-02

Downgrades

Strong Buy

Hold

Reason

JonesResearch analyst Justin Walsh downgraded BioLineRx to Hold from Buy without a price target following the Q4 report. BioLineRx is on "sounder financial footing" following cessation of U.S. commercial operations with a cash runway that extends into the second half of 2026, the analyst tells investors in a research note. However, the firm sees the stock remaining range bound until the company's pipeline assets are in-licensed or motixafortide generates additional favorable data in pancreatic cancer and gene therapy indications.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$9 → $26

2025-03-31

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$9 → $26

2025-03-31

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$21 → $9

2024-11-25

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$21 → $9

2024-11-25

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$21

2024-11-06

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$21

2024-11-06

Reiterates

Strong Buy

Reason

Jones Trading

Justin Walsh

Strong Buy

Initiates

2024-09-04

Reason

Jones Trading

Justin Walsh

Price Target

2024-09-04

Initiates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$21

2024-06-03

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$21

2024-06-03

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is -0.56, compared to its 5-year average forward P/E of -1.34. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.34

Current PE

-0.56

Overvalued PE

0.21

Undervalued PE

-2.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.31

Current EV/EBITDA

-0.45

Overvalued EV/EBITDA

-0.09

Undervalued EV/EBITDA

-2.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

12.60

Current PS

2.13

Overvalued PS

56.10

Undervalued PS

-30.91